Johnson & Johnson (NYSE:JNJ) Holdings Trimmed by Bivin & Associates Inc.

Bivin & Associates Inc. lowered its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 12.4% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,162 shares of the company’s stock after selling 872 shares during the quarter. Johnson & Johnson accounts for approximately 1.2% of Bivin & Associates Inc.’s investment portfolio, making the stock its 16th largest position. Bivin & Associates Inc.’s holdings in Johnson & Johnson were worth $1,094,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Johnson & Johnson by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 238,141,110 shares of the company’s stock valued at $42,205,749,000 after purchasing an additional 3,358,478 shares during the period. BlackRock Inc. boosted its position in shares of Johnson & Johnson by 0.4% in the 1st quarter. BlackRock Inc. now owns 200,799,189 shares of the company’s stock valued at $35,587,638,000 after purchasing an additional 777,837 shares during the period. Wellington Management Group LLP boosted its position in shares of Johnson & Johnson by 0.8% in the 1st quarter. Wellington Management Group LLP now owns 32,772,594 shares of the company’s stock valued at $5,808,286,000 after purchasing an additional 265,330 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Johnson & Johnson by 1.6% in the 1st quarter. Bank of New York Mellon Corp now owns 32,070,396 shares of the company’s stock valued at $5,683,837,000 after purchasing an additional 509,818 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Johnson & Johnson by 1.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock valued at $3,046,449,000 after purchasing an additional 328,297 shares during the period. Institutional investors own 68.59% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Raymond James decreased their price objective on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a research report on Wednesday, October 19th. StockNews.com assumed coverage on Johnson & Johnson in a research report on Wednesday, October 12th. They set a “strong-buy” rating for the company. Sanford C. Bernstein decreased their price objective on Johnson & Johnson from $194.00 to $190.00 in a research report on Wednesday, October 19th. Citigroup decreased their price objective on Johnson & Johnson from $201.00 to $198.00 in a research report on Wednesday, October 5th. Finally, Credit Suisse Group began coverage on Johnson & Johnson in a research report on Thursday, November 17th. They set a “neutral” rating and a $170.00 price objective for the company. Seven research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $181.33.

Johnson & Johnson Stock Up 0.1 %

Shares of JNJ stock opened at $177.01 on Thursday. The stock’s 50 day simple moving average is $168.35 and its 200 day simple moving average is $171.28. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69. The company has a market capitalization of $462.79 billion, a price-to-earnings ratio of 24.65, a PEG ratio of 3.49 and a beta of 0.57.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings data on Tuesday, October 18th. The company reported $2.55 earnings per share for the quarter, beating analysts’ consensus estimates of $2.49 by $0.06. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The business had revenue of $23.79 billion for the quarter, compared to the consensus estimate of $23.44 billion. During the same period last year, the business earned $2.60 EPS. The firm’s revenue was up 1.9% compared to the same quarter last year. As a group, research analysts predict that Johnson & Johnson will post 10.04 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd will be paid a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.55%. The ex-dividend date is Monday, November 21st. Johnson & Johnson’s payout ratio is 62.95%.

Johnson & Johnson announced that its board has initiated a share buyback plan on Wednesday, September 14th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the company to reacquire up to 1.2% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s leadership believes its stock is undervalued.

Insider Activity at Johnson & Johnson

In related news, CAO Robert J. Decker sold 16,928 shares of the firm’s stock in a transaction that occurred on Friday, November 18th. The stock was sold at an average price of $175.00, for a total value of $2,962,400.00. Following the transaction, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at approximately $2,707,775. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Johnson & Johnson news, CAO Robert J. Decker sold 16,928 shares of the firm’s stock in a transaction that occurred on Friday, November 18th. The stock was sold at an average price of $175.00, for a total value of $2,962,400.00. Following the sale, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,707,775. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Jennifer L. Taubert sold 76,923 shares of the firm’s stock in a transaction that occurred on Tuesday, November 22nd. The shares were sold at an average price of $176.78, for a total value of $13,598,447.94. Following the completion of the sale, the executive vice president now directly owns 126,456 shares in the company, valued at approximately $22,354,891.68. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 212,646 shares of company stock valued at $36,791,022. Corporate insiders own 0.35% of the company’s stock.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.